Procedure for Organizing a Post-FDA-approval Evaluation of Antidepressants

Farrokh Alemi; Hua Min; Melanie Yousefi; Laura K Becker; Christopher A Hane; Vijay S Nori; William Crown

doi:10.7759/cureus.29884

Back

Procedure for Organizing a Post-FDA-approval Evaluation of Antidepressants

Journal article

Peer reviewed

Procedure for Organizing a Post-FDA-approval Evaluation of Antidepressants

Farrokh Alemi, Hua Min, Melanie Yousefi, Laura K Becker, Christopher A Hane, Vijay S Nori and William Crown

Curēus (Palo Alto, CA), Vol.14(10), pp.e29884-e29884

10/03/2022

DOI: https://doi.org/10.7759/cureus.29884

Abstract

administrative data

antidepressants

cohorts

depression

effectiveness

Health Policy

Quality Improvement

Psychology

Purpose: The study reports the construction of a cohort used to study the effectiveness of antidepressants. Methods: The cohort includes experiences of 3,678,082 patients with depression in the United States on antidepressants between January 1, 2001, and December 31, 2018. A total of 10,221,145 antidepressant treatment episodes were analyzed. Patients who had no utilization of health services for at least two years, or who had died, were excluded from the analysis. Follow-up was passive, automatic, and collated from fragmented clinical services of diverse providers. Results: The average follow-up was 2.93 years, resulting in 15,096,055 person-years of data. The mean age of the cohort was 46.54 years (standard deviation of 17.48) at first prescription of antidepressant, which was also the enrollment event (16.92% were over 65 years), and most were female (69.36%). In 10,221,145 episodes, within the first 100 days of start of the episode, 4,729,372 (46.3%) continued their treatment, 1,306,338 (12.8%) switched to another medication, 3,586,156 (35.1%) discontinued their medication, and 599,279 (5.9%) augmented their treatment. Conclusions: We present a procedure for constructing a cohort using claims data. A surrogate measure for self-reported symptom remission based on the patterns of use of antidepressants has been proposed to address the absence of outcomes in claims. Future studies can use the procedures described here to organize studies of the comparative effectiveness of antidepressants.

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

25 Record Views

Details

Title: Procedure for Organizing a Post-FDA-approval Evaluation of Antidepressants
Creators: Farrokh Alemi - Health Adminstration and Policy, George Mason University, Fairfax, USA Health Administration and Policy, George Mason University, Fairfax, USA School of Nursing, George Mason University, Fairfax, USA Analytics, OptumLabs, Eden Prairie, USA Data Science, OptumLabs, Eden Prairie, USA Engineering, OptumLabs, Eden Prairie, USA Research, The Heller School for Social Policy and Management, Brandeis University, Waltham, USA
Hua Min - Health Adminstration and Policy, George Mason University, Fairfax, USA Health Administration and Policy, George Mason University, Fairfax, USA School of Nursing, George Mason University, Fairfax, USA Analytics, OptumLabs, Eden Prairie, USA Data Science, OptumLabs, Eden Prairie, USA Engineering, OptumLabs, Eden Prairie, USA Research, The Heller School for Social Policy and Management, Brandeis University, Waltham, USA
Melanie Yousefi - Health Adminstration and Policy, George Mason University, Fairfax, USA Health Administration and Policy, George Mason University, Fairfax, USA School of Nursing, George Mason University, Fairfax, USA Analytics, OptumLabs, Eden Prairie, USA Data Science, OptumLabs, Eden Prairie, USA Engineering, OptumLabs, Eden Prairie, USA Research, The Heller School for Social Policy and Management, Brandeis University, Waltham, USA
Laura K Becker - Health Adminstration and Policy, George Mason University, Fairfax, USA Health Administration and Policy, George Mason University, Fairfax, USA School of Nursing, George Mason University, Fairfax, USA Analytics, OptumLabs, Eden Prairie, USA Data Science, OptumLabs, Eden Prairie, USA Engineering, OptumLabs, Eden Prairie, USA Research, The Heller School for Social Policy and Management, Brandeis University, Waltham, USA
Christopher A Hane - Health Adminstration and Policy, George Mason University, Fairfax, USA Health Administration and Policy, George Mason University, Fairfax, USA School of Nursing, George Mason University, Fairfax, USA Analytics, OptumLabs, Eden Prairie, USA Data Science, OptumLabs, Eden Prairie, USA Engineering, OptumLabs, Eden Prairie, USA Research, The Heller School for Social Policy and Management, Brandeis University, Waltham, USA
Vijay S Nori - Health Adminstration and Policy, George Mason University, Fairfax, USA Health Administration and Policy, George Mason University, Fairfax, USA School of Nursing, George Mason University, Fairfax, USA Analytics, OptumLabs, Eden Prairie, USA Data Science, OptumLabs, Eden Prairie, USA Engineering, OptumLabs, Eden Prairie, USA Research, The Heller School for Social Policy and Management, Brandeis University, Waltham, USA
William Crown
Publication Details: Curēus (Palo Alto, CA), Vol.14(10), pp.e29884-e29884
Publisher: Cureus
Identifiers: 9924211581901921
Academic Unit: Institute for Global Health and Development
Language: English
Resource Type: Journal article

Procedure for Organizing a Post-FDA-approval Evaluation of Antidepressants

Abstract

UN Sustainable Development Goals (SDGs)

Metrics

Details

Brandeis University Social media